RxDoctor Payments Data

Nathaniel Stocker, APRN

Family · Columbia, SCNPI 1679041297

Payments from drug & device makers

$3,732in general payments, 2019–2025

Across 233 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Lilly USA, LLC$464
  • Pfizer$331
  • Merck$264
  • Axsome Therapeutics, Inc.$228
  • Abbott$183
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,732 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$129,368
Medicare patients
148
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$51,831
JardianceEmpagliflozin43$47,987
MounjaroTirzepatide35$47,307
FarxigaDapagliflozin Propanediol46$38,311
EliquisApixaban38$31,307
LinzessLinaclotide31$30,318
TrulicityDulaglutide17$18,735
XareltoRivaroxaban15$15,125
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,534
JanuviaSitagliptin Phosphate14$10,233
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,643
Novolog FlexpenInsulin Aspart14$2,556
Atorvastatin Calcium208$2,263
Pregabalin25$1,765
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$464$66,98864 claims
Novo NordiskOzempic$173$51,83151 claims
Boehringer IngelheimJardiance$33$47,98743 claims
AstraZenecaFarxiga$154$38,31146 claims
AbbVieLinzess, Synthroid$736$31,78455 claims
PfizerEliquis$331$31,30738 claims
GSKTrelegy Ellipta$62$11,53418 claims
MerckJanuvia$264$10,23314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →